APRE Aprea Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1781983 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-8.5%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-62.8%
ROA-53.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.1%
Debt / equity0.00x
Current ratio9.67x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.34M | $2.46M | $1.61M | $1.01M | $1.64M | $1.91M | $2.48M | $2.36M |
| SG&A expense | $1.83M | $1.57M | $1.82M | $1.64M | $1.48M | $1.59M | $1.76M | $1.07M |
| Operating income | -$5.17M | -$4.03M | -$3.43M | -$2.64M | -$3.12M | -$3.39M | -$4.09M | -$3.23M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$4.81M | -$3.59M | -$3.29M | -$2.46M | -$2.97M | -$3.24M | -$3.93M | -$2.89M |
| EBITDA | -$5.17M | -$4.03M | -$3.42M | -$2.64M | -$3.11M | -$3.38M | -$4.08M | -$3.22M |
| EPS (basic) | -0.09 | -0.07 | -0.22 | — | -0.47 | -0.53 | -0.66 | — |
| EPS (diluted) | -0.09 | -0.07 | -0.22 | — | -0.47 | -0.53 | -0.66 | — |
| Weighted avg. shares (diluted) | 53.68M | 53.48M | 14.69M | — | 6.37M | 6.08M | 5.99M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $37.85M | $41.23M | $46.47M | $14.60M | $13.72M | $16.53M | $19.28M | $22.89M |
| Current assets | $38.44M | $41.91M | $47.25M | $15.56M | $13.94M | $16.93M | $19.83M | $23.58M |
| PP&E, net | $62,443 | $64,033 | $54,379 | $59,807 | $65,236 | $70,665 | $76,093 | $81,522 |
| Total assets | $38.81M | $42.29M | $47.61M | $15.93M | $14.32M | $17.31M | $20.22M | $23.98M |
| Current liabilities | $3.97M | $3.09M | $5.30M | $2.76M | $2.68M | $3.17M | $3.36M | $3.36M |
| Total liabilities | $4.70M | $3.82M | $6.02M | $3.49M | $3.41M | $3.90M | $4.67M | $4.67M |
| Shareholders' equity | $34.11M | $38.47M | $41.59M | $12.44M | $10.91M | $13.41M | $15.55M | $19.31M |
| Shares outstanding | 14.19M | 12.39M | 11.98M | 8.19M | 5.98M | 5.75M | 5.51M | 5.48M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.73M | -$3.28M | -$2.76M | -$2.96M | -$3.17M | -$3.13M | -$3.63M | -$3.51M |
| Capital expenditure | $1 | — | — | — | — | — | — | $0 |
| Free cash flow | -$3.73M | — | — | — | — | — | — | -$3.51M |
| Investing cash flow | -$1 | — | — | — | — | — | — | $0 |
| Financing cash flow | $342,000 | -$1.94M | $34.62M | $3.84M | $357,940 | $384,879 | $55,849 | $134,405 |
| Depreciation & amortization | $5,905 | $5,746 | $5,428 | $5,429 | $5,429 | $5,428 | $5,429 | $5,428 |
| Stock-based compensation | $100,000 | $100,000 | — | — | $100,000 | $100,000 | $100,000 | — |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.